M&A Deal Summary

Biosynex Acquires ProciseDx

On June 13, 2023, Biosynex acquired medical products company ProciseDx

Acquisition Highlights
  • This is Biosynex’s 4th transaction in the Medical Products sector.
  • This is Biosynex’s 2nd transaction in the United States.
  • This is Biosynex’s 1st transaction in California.

M&A Deal Summary

Date 2023-06-13
Target ProciseDx
Sector Medical Products
Buyer(s) Biosynex
Deal Type Add-on Acquisition

Target

ProciseDx

San Diego, California, United States
ProciseDx is a vitro diagnostics (IVD) company with a proprietary instrument platform and portfolio of Point of Care diagnostic tests, based in San Diego, California.

Search 215,029 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Biosynex

Illkirch-Graffenstaden, France

Category Company
Founded 2005
Sector Life Science
Employees176
Revenue 27M EUR (2016)
DESCRIPTION

Biosynex is a designer and distribution of rapid diagnostic tests. Biosynex develops, manufactures and markets Medical Devices for Screening, Diagnostics, and Prevention in a permanent quest for excellence. Biosynex was founded in 2008 and is based in Illkirch-Graffenstaden, France.


DEAL STATS #
Overall 4 of 5
Sector: Medical Products M&A 4 of 4
Type: Add-on Acquisition M&A Deals 2 of 2
State: California M&A 1 of 1
Country: United States M&A 2 of 2
Year: 2023 M&A 2 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-01-31 Chembio Diagnostics

Hauppauge, New York, United States

Chembio Diagnostics is a developer, manufacturer and marketer of proprietary rapid diagnostic tests in the growing $8.0 billion point-of-care testing market. Chembio markets each of its DPP® HIV 1/2 Assay, HIV 1/2 STAT-PAK® Assay, and SURE CHECK® HIV 1/2 Assay, with these Chembio brand names, in the U.S. and internationally both directly and through third-party distributors. Chembio Diagnostics was incorporated in 1985 and is based in Hauppauge, New York.

Buy $17M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-09-29 TheraDiag

Croissy-Beaubourg, France

TheraDiag develops, produces, and markets in vitro diagnostics products in France and internationally. It offers auto-immunity products, such as FIDIS kits that allow detection of multiple analytes from the same sample in a single assay. TheraDiag was founded in 1986 and is based in Croissy-Beaubourg, France.

Buy -